NCT06276764Enrolling by invitation
The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)
The LINFU® U.S. Registry for the Detection of Dysplasia and Pancreatic Ductal Adenocarcinoma (PDAC) in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)
Source: ClinicalTrials.gov · Last updated 6 Aug 2026
Brief summary (registry, in English)
In this study, LINFU® will be evaluated in patients who have been identified with IPMN to determine if it can be used to help identify early, pancreatic ductal adenocarcinoma and its noninvasive precursor lesions (dysplasia). The study will also help determine if LINFU® results in earlier intervention, treatment and improvement in patient outcomes.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 18 Feb 2024
- Start date
- 15 Oct 2024
- Primary completion date
- 30 Sept 2034
- Lead sponsor
- Adenocyte, LLC
- Diseases
- Pancreatic cancer
- NCT number
- NCT06276764
What you commit to
- Study type: Observational
- Planned participants: 500
- From 15 Oct 2024 to the primary completion date, 30 Sept 2034
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with IPMN that has been subjected to FNA or biopsy prior to the LINFU procedure
Other illness
- Patient with known allergy to the microbubble contrast agent or secretin
- Study Design Overview:
Age
- Patient under the age of 18 and over the age 90
Other
- Contraindications to LINFU® as determined by study investigators:
- Patient with uncorrectable coagulopathy
- Patient that cannot undergo anesthesia due to cardiopulmonary contraindication as deemed by the anesthesiologist
- Unstable medically (cardiopulmonary, neurologic, or cardiovascular status)
- Patients with pancreatic cystic neoplasms other than IPMN i.e. mucinous cystic neoplasms, serous cystic neoplasms and other rare cystic lesions
- Pregnant females will be excluded
- Patient that is unable to provide informed consent
Who the study is looking for
- Both males and females will be enrolled and must be at least 18 years of age and under age of 90
- Patients with a documented history of IPMN by any imaging method.
- All patients must undergo contemporaneous imaging (within 90 days before or after the LINFU® procedure) with one or more of the following: EUS, CH-EUS, CEUS, MRI/MRCP, PET/CT, CT
- Patients undergoing EUS-FNA may be enrolled but the FNA must be performed after the LINFU® procedure
- Institutional Review Board (IRB)-approved consent must be signed by patients to participate in this study.
Age in the registry: 18 years to 90 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Manhattan Endoscopy Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.